Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase II Clinical Study of Efdamrofusp Alfa, a First-In-Class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

Innovent Biologics, Inc. accounced the completion of first patient dosing in the Phase II clinical study of efdamrofusp alfa, a recombinant human VEGFR-antibody human complement receptor 1 fusion protein, for the treatment of diabetic macular edema.